<DOC>
	<DOC>NCT01635738</DOC>
	<brief_summary>Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus paracasei GMNL-133(LP), Lactobacillus fermentum GM-090 (LF), and Lactobacillus paracasei GMNL-133(LP) with Lactobacillus fermentum GM-090 (LF) combination products used for adjuvant treatment of atopic dermatitis and asthma.</brief_summary>
	<brief_title>Probiotics and Allergic Diseases</brief_title>
	<detailed_description>The main purpose: To investigate if Lactobacillus paracasei GMNL-133(LP), Lactobacillus fermentum GM-090(LF), Lactobacillus paracasei GMNL-133 (LP) with Lactobacillus fermentum GM-090 (LF) combination products could be used for the adjuvant treatment of atopic dermatitis and asthma. The Secondary Objective: To investigate whether probiotics consumption improve the quality of life and allergic symptoms to different people with Lactobacillus paracasei GMNL-133 (LP), Lactobacillus fermentum GM-090 (LF) and Lactobacillus paracasei GMNL-133(LP) and Lactobacillus fermentum GM-090 (LF) combination products.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1. Age between 1 year old and 18 years old, 2. AD cases fulfill the diagnostic criteria by Hannifin and Rajka. 3. Atopy as shown by at least one positive skin test (weal size ≧ 3mm) or one positive MAST (RAST) (IgE ≧ 0.7 kU/L) test to any common food or environmental allergens. 1. Systematic corticosteroid, immunosuppressive therapy, or antimycotics treatment during the 4 weeks, antihistamines, and singulair during the 7 days before enrollment 2. Probiotic preparations used within 2 weeks before entering the study 3. Use of antibiotics now or other oral medications that will interfere the results 4. If they had immune deficiency disease or other major medical problems 5. If they had participated in another clinical study during the past month. 6. Subjects are undergoing desensitization therapy within 3 months prior to the screening period. 7. Subjects have participated investigational drug trial within 4 weeks before entering this study. 8. Subjects are pregnant, lactating or planning to become pregnant. 9. Subjects with any other serious diseases considered by the investigator that could interfere with the performance of SCORAD score result. 10. Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Probiotics</keyword>
	<keyword>Lactobacillus paracasei GMNL-133</keyword>
	<keyword>Lactobacillus fermentum GM-090</keyword>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Asthma</keyword>
	<keyword>Lactobacillus paracasei</keyword>
	<keyword>Lactobacillus fermentum</keyword>
	<keyword>efficacy and safety</keyword>
</DOC>